• SciBase secured its first US private payer coverage for Nevisense after Highmark Blue Cross Blue Shield issued a positive medical policy.
• The decision shifts eligible use from mostly cash-pay to reimbursed care, easing a key barrier to wider adoption in the US.
• The policy deems electrical impedance spectroscopy medically necessary for dermatologists assessing clinically atypical suspicious pigmented lesions when a biopsy is being considered.
• Highmark covers more than 7 million members across multiple states.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.